Vankomicin PharmaSwiss 1000 mg prašek za raztopino za infundiranje Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

vankomicin pharmaswiss 1000 mg prašek za raztopino za infundiranje

pharmaswiss Česká republika s.r.o. - vankomicin - prašek za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin

Glukozamin "Pharma Nord" 400 mg trde kapsule Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glukozamin "pharma nord" 400 mg trde kapsule

pharma nord-mah - glukozamin - kapsula, trda - glukozamin 400 mg / 1 kapsula - glukozamin

Glukozamin "Pharma Nord" 400 mg trde kapsule Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glukozamin "pharma nord" 400 mg trde kapsule

pharma nord-mah - glukozamin - kapsula, trda - glukozamin 400 mg / 1 kapsula - glukozamin

Clopidogrel Acino Pharma Unión Europea - esloveno - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - clopidogrel je navedeno pri odraslih za preprečevanje atherothrombotic dogodkov v:bolnike, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od 7 dni do manj kot 6 mesecev) ali sedež periferne arterijske bolezni. za nadaljnje informacije, prosimo, preberite razdelek 5.

Clopidogrel Acino Pharma GmbH Unión Europea - esloveno - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - clopidogrel je navedeno pri odraslih za preprečevanje atherothrombotic dogodkov v:bolnike, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od 7 dni do manj kot 6 mesecev) ali sedež periferne arterijske bolezni. za nadaljnje informacije, prosimo, preberite razdelek 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Unión Europea - esloveno - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotična sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Rivastigmine 1 A Pharma Unión Europea - esloveno - EMA (European Medicines Agency)

rivastigmine 1 a pharma

1 a pharma gmbh - rivastigmin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - simptomatsko zdravljenje blage do zmerno hude alzheimerjeve demence. simptomatsko zdravljenje blage do zmerno hude demence pri bolnikih z idiopatsko parkinsonovo boleznijo.

Pioglitazone Teva Pharma Unión Europea - esloveno - EMA (European Medicines Agency)

pioglitazone teva pharma

teva pharma b.v. - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena.

Bortezomib PharmaSwiss 3,5 mg prašek za raztopino za injiciranje Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bortezomib pharmaswiss 3,5 mg prašek za raztopino za injiciranje

pharmaswiss Česká republika s.r.o. - bortezomib - prašek za raztopino za injiciranje - bortezomib 3,5 mg / 1 viala - bortezomib

Protaminijev sulfat LEO Pharma 1400 anti-heparin i.e./ml raztopina za injiciranje ali infundiranje Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

protaminijev sulfat leo pharma 1400 anti-heparin i.e./ml raztopina za injiciranje ali infundiranje

leo pharma a/s - protamininijev sulfat - raztopina za injiciranje/infundiranje - protamininijev sulfat 10 mg / 1 ml - protamin